---
schema_version: "secwatch.filing_event.v1"
accession: "0001650664-25-000081"
form_type: "8-K"
ticker: "EDIT"
cik: "0001650664"
company_name: "Editas Medicine, Inc."
filed_at: "2025-05-14T23:59:59+00:00"
generated_at: "2026-05-21T08:53:32.919405+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Editas reports in vivo HSC editing up to 48% HBG1/2, exceeding 25% therapeutic threshold

## Summary
- Single dose of proprietary tLNP achieved up to 47% HBG1/2 editing in NHP HSCs and 48% in humanized mouse long-term HSCs.
- Both studies exceeded the ≥25% editing threshold predicted for therapeutic benefit in sickle cell disease and beta thalassemia.
- Preliminary biodistribution shows significant liver de-targeting with tLNP vs. standard LNPs.
- Data presented at ASGCT 2025; supports development of in vivo gene editing medicine using AsCas12a-based reni-cel approach.
- Clinical validation of HBG1/2 promoter editing previously demonstrated with reni-cel leading to increased HbF and total Hb.

## SEC filing metadata
- accession: 0001650664-25-000081
- form_type: 8-K
- ticker: EDIT
- cik: 0001650664
- company_name: Editas Medicine, Inc.
- filed_at: 2025-05-14T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1650664/000165066425000081/0001650664-25-000081-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1650664/000165066425000081/edit-20250514.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001650664-25-000081
- JSON: https://secwatch.observer/filing/0001650664-25-000081.json
- Plain text: https://secwatch.observer/filing/0001650664-25-000081.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.